An observational study in Acute Myocardial Infarction, sponsored by Collegium Medicum w Bydgoszczy. Completed at 2 sites in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-02-26.
Sponsored by Collegium Medicum w Bydgoszczy · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in ST Elevation Myocardial Infarction with a site in Poland — 3 open to participants now, 4 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Poland.
Among the 30 studies in ST Elevation Myocardial Infarction with a site in Poland, this one is one of 3 that started in 2018, is one of 7 observational ones, and was the 18th registered.
851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →3 of the 30 studies in ST Elevation Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Poland, Argentina, Australia and 11 more countries
Ages 18+
Michał Jaśkiewicz · Sites in Poland
Ages 18–80
Collegium Medicum w Bydgoszczy · Sites in Poland
Ages 18–80
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 9 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is below the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 303 across the 23 interventional studies, 100 across the 7 observational. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 30 have an industry lead sponsor. The 10 most frequent:
Collegium Medicum w Bydgoszczy is the lead sponsor of 26 studies on the registry; 4 are open to participants now.
Collegium Medicum w Bydgoszczy has 5 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in ST Elevation Myocardial Infarction with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in ST Elevation Myocardial Infarction with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare circadian variability of antiplatelet effect of prasugrel and ticagrelor maintenance doses during the initial days after acute myocardial infarction.
Prasugrel and ticagrelor are two oral P2Y12 receptor antagonists recommended as a part of dual antiplatelet therapy with aspirin in patients with acute myocardial infarction. Both drugs exert comparable antiplatelet effect following a loading dose. However, pharmacodynamic differences exist between these P2Y12 receptor inhibitors. Prasugrel is a prodrug that requires hepatic activation and permanently binds to platelet P2Y12 receptors, whereas ticagrelor is an active drug and blocks P2Y12 receptors reversibly. Another important difference is that prasugrel maintenance dose is administered once daily, while ticagrelor requires next dosage every 12 hours. These fundamental distinctions may affect the degree of platelet inhibition on maintenance doses during the first days after acute myocardial infarction.
Patients with acute myocardial infarction treated invasively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
Drug: Prasugrel
Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
Drug: Ticagrelor
Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
Also known as: Efient
Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
Also known as: Brilique
Circadian variability of platelet inhibition assessed with VASP
Platelet inhibition evaluated with VASP assay at 8:00, 12:00, 16:00 and 20:00
Time frame: Day 4 after acute myocardial infarction
Circadian variability of platelet inhibition assessed with Multiplate
Platelet inhibition evaluated with Multiplate at 8:00, 12:00, 16:00 and 20:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity at 8:00 assessed with VASP
Number of patients with high platelet reactivity evaluated with VASP assay at 8:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity at 12:00 assessed with VASP
Number of patients with high platelet reactivity evaluated with VASP assay at 12:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 16:00 assessed with VASP
Number of patients with high platelet reactivity evaluated with VASP assay at 16:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 20:00 assessed with VASP
Number of patients with high platelet reactivity evaluated with VASP assay at 20:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 08:00 assessed with Multiplate
Number of patients with high platelet reactivity evaluated with Multiplate at 08:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 12:00 assessed with Multiplate
Number of patients with high platelet reactivity evaluated with Multiplate at 12:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 16:00 assessed with Multiplate
Number of patients with high platelet reactivity evaluated with Multiplate at 16:00
Time frame: Day 4 after acute myocardial infarction
High platelet reactivity 20:00 assessed with Multiplate
Number of patients with high platelet reactivity evaluated with Multiplate at 20:00
Time frame: Day 4 after acute myocardial infarction
Ran from Feb 2018 to primary completion in Feb 2019, 12 months.
Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 107. This study's 12 months is below that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 20 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Collegium Medicum w Bydgoszczy